Literature DB >> 11733363

Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia.

F Kumaki1, K Matsui, T Kawai, Y Ozeki, Z X Yu, V J Ferrans, W D Travis.   

Abstract

To investigate the association between the expression of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) and the clinicopathological features in lepidic and invasive components of adenocarcinoma of the lung, we performed immunostaining for type IV collagen, various MMPs, and TIMPs in 27 cases of invasive adenocarcinomas and 5 cases of atypical adenomatous hyperplasia of alveolar epithelial cells (AAH). Mean extent of lepidic growth was 61% and the survival was significantly better in cases with 50% or more lepidic component. The preservation of type IV collagen in lepidic areas correlated inversely with lymphatic or vascular invasion (P = 0.02 and 0.002, respectively). Five-year survival was reduced in cases showing destruction of type IV collagen (P = 0.004) or expression of MMP-2 (P = 0.008) in lepidic areas. MMP-2 co-localized with MT-1-MMP (its activating enzyme) and TIMP-2 in neoplastic cells. Reactivity for other MMPs and TIMPs did not correlate with destruction of type IV collagen or prognosis. Type IV collagen was preserved in all cases of AAH. MMP-2, but not MT-1-MMP, was expressed in two of the five cases of AAH. Immunostaining for type IV collagen MMP-2 is useful in evaluating the prognosis of the lung.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11733363      PMCID: PMC1850594          DOI: 10.1016/S0002-9440(10)63064-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  30 in total

1.  Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy.

Authors:  S Garbisa; G Scagliotti; L Masiero; C Di Francesco; C Caenazzo; M Onisto; M Micela; W G Stetler-Stevenson; L A Liotta
Journal:  Cancer Res       Date:  1992-08-15       Impact factor: 12.701

2.  Processing of a precursor of 72-kilodalton type IV collagenase/gelatinase A by a recombinant membrane-type 1 matrix metalloproteinase.

Authors:  T Kinoshita; H Sato; T Takino; M Itoh; T Akizawa; M Seiki
Journal:  Cancer Res       Date:  1996-06-01       Impact factor: 12.701

3.  Pulmonary scar cancer. A pathologic reappraisal.

Authors:  I T Kung; I O Lui; S L Loke; M A Khin; C K Mok; W K Lam; S Y So
Journal:  Am J Surg Pathol       Date:  1985-06       Impact factor: 6.394

4.  Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis.

Authors:  M Tokuraku; H Sato; S Murakami; Y Okada; Y Watanabe; M Seiki
Journal:  Int J Cancer       Date:  1995-10-20       Impact factor: 7.396

5.  Morphometric study of adenocarcinomas and hyperplastic epithelial lesions in the peripheral lung.

Authors:  T Kodama; S Biyajima; S Watanabe; Y Shimosato
Journal:  Am J Clin Pathol       Date:  1986-02       Impact factor: 2.493

6.  Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study.

Authors:  I Shima; Y Sasaguri; J Kusukawa; H Yamana; H Fujita; T Kakegawa; M Morimatsu
Journal:  Cancer       Date:  1992-12-15       Impact factor: 6.860

7.  A matrix metalloproteinase expressed on the surface of invasive tumour cells.

Authors:  H Sato; T Takino; Y Okada; J Cao; A Shinagawa; E Yamamoto; M Seiki
Journal:  Nature       Date:  1994-07-07       Impact factor: 49.962

8.  Small adenocarcinoma of the lung. Histologic characteristics and prognosis.

Authors:  M Noguchi; A Morikawa; M Kawasaki; Y Matsuno; T Yamada; S Hirohashi; H Kondo; Y Shimosato
Journal:  Cancer       Date:  1995-06-15       Impact factor: 6.860

9.  Activity of type IV collagenases in benign and malignant breast disease.

Authors:  B Davies; D W Miles; L C Happerfield; M S Naylor; L G Bobrow; R D Rubens; F R Balkwill
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

10.  Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans.

Authors:  A E Kossakowska; S A Huchcroft; S J Urbanski; D R Edwards
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

View more
  5 in total

1.  Increased collagenase activity in macrophages from bronchial lavage as a diagnostic marker of non-small cell lung cancer.

Authors:  Y Hakoda; Y Ito; A Nagate; K Minemura; K Utsumi; M Aoshima; K Ohyashiki
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

Review 2.  Prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Lin Zhu; Hong Yu; Shi-Yuan Liu; Xiang-Sheng Xiao; Wei-Hua Dong; Yi-Nan Chen; Wei Xu; Tong Zhu
Journal:  PLoS One       Date:  2015-04-23       Impact factor: 3.240

3.  Identification of genes associated with matrix metalloproteinases in invasive lung adenocarcinoma.

Authors:  Weiqing Li; Xugang Zhang; Zhitian Li; Fusheng Jiang; Hongwei Zhao; Bo Wei
Journal:  Oncol Lett       Date:  2018-05-10       Impact factor: 2.967

4.  A Strong Decrease in TIMP3 Expression Mediated by the Presence of miR-17 and 20a Enables Extracellular Matrix Remodeling in the NSCLC Lesion Surroundings.

Authors:  Karolina H Czarnecka; Bartosz Szmyd; Magda Barańska; Marcin Kaszkowiak; Jacek Kordiak; Adam Antczak; Dorota Pastuszak-Lewandoska; Ewa Brzeziańska-Lasota
Journal:  Front Oncol       Date:  2019-12-13       Impact factor: 6.244

5.  The expression and clinical significance of matrix metalloproteinase 7 and tissue inhibitor of matrix metalloproteinases 2 in clear cell renal cell carcinoma.

Authors:  Hongsheng Lu; Zhaohui Yang; Hui Zhang; Meifu Gan; Tao Zhou; Siling Wang
Journal:  Exp Ther Med       Date:  2012-12-17       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.